Suven Life Sciences Limited (NSE:SUVEN)

Market Cap	32.31B +10.4%
Revenue (ttm)	70.62M -6.8%
Net Income	-2.75B
EPS	-12.35
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,868
Average Volume	352,044
Open	139.90
Previous Close	139.29
Day's Range	131.63 - 140.40
52-Week Range	102.50 - 299.99
Beta	0.36
RSI	31.27
Earnings Date	Jan 29, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 138
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUVEN

Financial Performance

In fiscal year 2025, Suven Life Sciences's revenue was 66.56 million, a decrease of -43.08% compared to the previous year's 116.93 million. Losses were -1.61 billion, 53.0% more than in 2024.